Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276

Watchlist Manager
Jiangsu Hengrui Pharmaceuticals Co Ltd Logo
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Watchlist
Price: 63.38 CNY 0.48% Market Closed
Market Cap: 404.3B CNY

Jiangsu Hengrui Pharmaceuticals Co Ltd
Interest Income Expense

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Jiangsu Hengrui Pharmaceuticals Co Ltd
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Interest Income Expense
Â¥649.7m
CAGR 3-Years
-2%
CAGR 5-Years
3%
CAGR 10-Years
19%
C
CSPC Pharmaceutical Group Ltd
HKEX:1093
Interest Income Expense
-Â¥90.2m
CAGR 3-Years
-19%
CAGR 5-Years
N/A
CAGR 10-Years
-9%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Interest Income Expense
Â¥559.3m
CAGR 3-Years
7%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Interest Income Expense
Â¥391.3m
CAGR 3-Years
51%
CAGR 5-Years
28%
CAGR 10-Years
17%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Interest Income Expense
Â¥1.3B
CAGR 3-Years
89%
CAGR 5-Years
-3%
CAGR 10-Years
35%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Interest Income Expense
Â¥258.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Jiangsu Hengrui Pharmaceuticals Co Ltd
Glance View

Nestled in the throbbing economic heart of China's Jiangsu province, Jiangsu Hengrui Pharmaceuticals Co Ltd has carved a niche as a formidable player in the global pharmaceutical landscape. Established in 1970, this company has evolved from its humble beginnings into a powerhouse known for its relentless focus on research and development, a keystone in its operational strategy. Hengrui has built a diverse portfolio of products, primarily focusing on oncological, cardiovascular, and anti-diabetic therapeutics. The company leverages its state-of-the-art R&D facilities and a team of top-tier scientists to innovate and advance new treatment solutions, which are then patented to ensure exclusivity and competitive market positioning. In addition to its robust R&D-driven pipeline, Hengrui thrives through strategic collaborations and international partnerships that enhance its market reach and deepen its competitive moat. Revenue generation springs from a dual-engine model: sales of proprietary drugs and a burgeoning generic drug segment that ensures steady cash flow. Furthermore, Hengrui's ability to navigate the intricate regulatory landscapes of different countries enables it to market its innovative therapies globally, thus broadening its revenue streams. With an eye toward sustainable growth, the company continually reinvests a significant portion of its profits back into R&D, sustaining its cycle of innovation and market leadership, while also playing a vital role in meeting global healthcare needs.

Intrinsic Value
48.12 CNY
Overvaluation 24%
Intrinsic Value
Price

See Also

What is Jiangsu Hengrui Pharmaceuticals Co Ltd's Interest Income Expense?
Interest Income Expense
649.7m CNY

Based on the financial report for Sep 30, 2025, Jiangsu Hengrui Pharmaceuticals Co Ltd's Interest Income Expense amounts to 649.7m CNY.

What is Jiangsu Hengrui Pharmaceuticals Co Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
19%

Over the last year, the Interest Income Expense growth was 37%. The average annual Interest Income Expense growth rates for Jiangsu Hengrui Pharmaceuticals Co Ltd have been -2% over the past three years , 3% over the past five years , and 19% over the past ten years .

Back to Top